Covid-19 has shone a spotlight on biotechnology investment opportunities, drawing attention from new corners of the PE world. But exciting new opportunities also come with fresh challenges, writes Alessia Argentieri
GP intends to acquire a stake in acquirer Dustin, which Altor listed in 2015
According to Borsen, the GP's stake is more than 35% and that the deal valued Luxion at almost DKK 1bn (€134.5m)
Fund enables Phoenix to build portfolios with exposure to venture capital investments for its policyholders
Despite the pandemic, 2020 was one of the best years for venture capital, tech companies in both buyout and VC markets, and established GPs who raised record-breaking amounts, according to Argentum's 2020 State of Nordic Private Equity report. Joachim...